세계의 바이오의약품 첨가제 시장 : 업계 동향 및 예측 - 생물 제제 유형별, 첨가제 유형별, 기업 규모별, 사업 규모별, 주요 지역별

Biopharmaceutical Excipients Market: Industry Trends and Global Forecasts - Distribution by Type of Biologics, Type of Excipient, Company Size, Scale of Operation and Key Geographies

US $ 4,799 ￦ 6,873,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 10,023,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,179,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,778,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 바이오의약품 첨가제 시장 : 개요

바이오의약품 첨가제 시장 규모는 2035년까지 예측 기간 동안 4.8%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 현재 27억 3,000만 달러에서 2035년까지 45억 8,000만 달러로 성장할 것으로 예측됩니다.

시장 세분화는 시장 규모와 기회 분석을 다음 매개 변수로 구분합니다.

생물 제제 유형별

• 항체
• 백신
• 세포 치료제
• 기타

첨가제 유형별

• 탄수화물
• 폴리머
• 용해제 및 계면활성제
• 폴리올
• 단백질 및 아미노산
• 기타

기업 규모별

• 소규모
• 중규모
• 대기업 및 초대형

사업 규모별

• 전임상
• 임상시험
• 상업

주요 지역별

• 북미
• 유럽
• 아시아
• 라틴아메리카
• 중동 및 북아프리카
• 기타 지역

세계의 바이오의약품 첨가제 시장 : 성장 및 동향

생물 제제의 개발에 중요한 역할을 하기 위해, 생물 제제용 첨가제에 대한 수요는 지난 수년간 크게 증가하고 있습니다. 이러한 바이오의약품 첨가제는 원료 약물(API)의 pH와 강장도를 조절하여 생물학적 제제의 용해도와 생체이용률을 향상시킵니다. 그러나, 생물 제제용 첨가제의 제조 공정은 매우 복잡하고 자본 집약적이기 때문에 현대의 많은 생물 제제 개발 기업들은 GMP 등급 참가제 공급을 CMO에 의존하는 것을 선호하고 있습니다. 또한 임상 및 상업 규모에서 바이오의약품 첨가제 수요 증가에 대응하기 위해 이 분야의 전문 지식을 갖춘 CMO는 향후 몇 년 동안 그 능력과 기존 능력을 확대할 것으로 예측됩니다.

조사 중 지질, 트레할로스, 유당, 만니톨, 숙신산염, Tween 20, 벤질 알코올 등 바이오의약품 첨가제의 제조 서비스를 제공하는 다양한 기업을 확인했습니다. 이러한 기업들은 혁신적인 바이오 의약품의 안정성과 효능을 높이기 위해 공동 가공된 다기능 바이오의약품 첨가제의 개발에 중점을 둡니다. 실제로 지난 30년간 바이오 의약품 제조업체는 바이오 의약품 제형의 보존가능 기간을 3배로 늘린다고 주장하는 몇 가지 우수한 부형제를 개발해 왔습니다.

세계의 바이오의약품 첨가제 시장 : 주요 인사이트

이 보고서는 세계 바이오의약품 첨가제 시장의 현재 상태를 조사하고 잠재적 성장 기회를 확인합니다. 주요 조사 결과는 다음과 같습니다.

• 현재, 약 45사가 다양한 유형의 바이오의약품 첨가제를 생물학적 제제 개발자에게 제공하고 있다고 주장하고 있으며, 이들 기업은 세계의 규제 기준에 준거해 사업을 전개하고 있습니다.
• 스폰서의 진화하는 요구에 부응하기 위해, 바이오의약품 첨가제를 제공하는 기업은 다양한 지역에서 존재감을 나타내고 있습니다.

• 시장 상황는 단편화되고 있어 다양한 유형의 생물 제제용 첨가제의 제조에 종사하는 기존 기업과 신규 참가 기업의 양쪽이 존재하고 있습니다.
• 90% 근처의 기업이 모든 규모의 액체 제제용 부형제를 제공하는데 필요한 능력과 전문지식을 가지고 있다고 주장하고 있습니다.
• 제조업체의 대부분(-75%)은 선진 지역에 거점을 두고 있지만, 인도나 중국 등의 아시아 제국에서는 최근 많은 참가 기업이 대두해 오고 있습니다.
• 제조업체의 60% 근처가, 백신이나 단백질 펩티드 베이스의 치료제에 바이오 의약품의 부형제를 제공하고 있다고 주장하고 있습니다.
• 각사는 각각의 포트폴리오를 강화해, 진화하는 업계 벤치마크에의 준거를 추진하기 위해, 기존의 능력을 꾸준히 확대하고 있습니다.
• 바이오의약품 첨가제에 초점을 맞춘 파트너십 증가는 이 영역에서의 이해관계자의 관심의 고조를 뒷받침하는 것으로, 과거 3년간에 이러한 거래가 가장 많이 체결되었습니다.
• 2020년 이후 이 분야에서의 파트너십 활동은 안정된 페이스로 증가하고 있습니다. 특기할 만한 것은 거래의 대부분이 지난 2년간에 성립했다는 것입니다.
• 이 영역에서는 과거 5년간에 40 이상의 계약이 맺어져 있으며, 그 중 32%가 판매 계약이었습니다.
• 기존의 참가 기업은 바이오의약품 첨가제에 관해 복수의 계약을 맺고 있습니다만, 그 대부분은 독자적인 바이오의약품 첨가제의 판매에 초점을 맞춘 것이었습니다.
• 북미에서 여러 계약을 맺은 기업의 예로는 ABITEC, Aceto, Evonik, Merck, Roquette를 들 수 있습니다(알파벳순).
• 바이오의약품 첨가제에 대한 수요 증가에 대응하기 위해, 제조업체는 최근, 많은 확장 계획을 실시했습니다.
• 확장 계획의 45% 이상이 제조 시설의 능력 확장에 중점을 두고 있으며, 이어 기존 시설의 확장(43%)이었습니다. 특기할 만한 것은 확장 계획의 대부분(78%)이 유럽과 북미에서 실시되었다는 것입니다.
• 이 시장의 공급 사이드는 중견 및 대형 바이오의약품 첨가제 제조업체가 견인하고 있습니다. 흥미롭게도, 현재 이용 가능한 생산 능력의 40% 근처가, 유럽에 있는 생산 공장에 설치되고 있습니다.
• 흥미롭게도 현재 사용 가능한 생산 능력의 거의 40%가 유럽의 생산 공장에 설치되어 있습니다.
• 생물 제제에 기초한 치료 개입에 대한 주목이 높아지는 가운데, 바이오의약품 첨가제 시장은 향후 10년간, 안정된 페이스로 성장할 것으로 예측됩니다.
• 이 기회는 다양한 생물 제제, 사업 규모, 주요 지역별로 분류될 것으로 예측됩니다.
• 북미와 유럽은 2035년까지 시장 점유율의 70% 이상을 차지할 것으로 예상되고 있습니다. 또 아시아태평양 지역의 시장은 장기적으로 비교적 빠른 속도(6.4%)로 성장할 것으로 보입니다. 게다가 2035년에는 항체용 바이오의약품 첨가제 시장이 시장 전체의 대부분의 점유율(52%)을 차지할 것으로 예상됩니다.

바이오의약품 첨가제 시장의 진출기업 예

• ABITEC
• Avantor
• BASF
• Corden Pharma
• DFE Pharma
• Evonik
• Kirsch Pharma
• Merck KGaA
• Pfanstiehl
• Roquette
• Spectrum Chemical Manufacturing
• SPI Pharma

본 보고서에서는 세계의 바이오의약품 첨가제 시장에 대해 조사했으며, 시장 개요와 함께 생물제제 유형별, 부형제 유형별, 기업 규모별, 사업 규모별 동향, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

제2장 주요 요약

제3장 서문

• 장의 개요
• 바이오의약품 첨가제
• 이상적인 부형제의 특성
• 바이오의약품 첨가제의 분류
• 바이오의약품 첨가제의 용도
• 규제 시나리오
• 결론

제4장 시장 상황

• 장의 개요
• 바이오의약품 첨가제 제조업체 : 시장 상황

제5장 기업 경쟁력 분석

• 장의 개요
• 전제 및 주요 파라미터
• 조사 방법
• 바이오의약품 첨가제 제조업체 : 기업 경쟁력 분석

제6장 기업 프로파일 : 바이오의약품 첨가제 제조업체

• 장의 개요
• ABITEC
• Avantor
• BASF Pharma
• Corden Pharma
• DFE Pharma
• Evonik
• Kirsch Pharma
• Merck KGaA
• Pfanstiehl
• Roquette
• Spectrum Chemical Manufacturing
• SPI Pharma

제7장 파트너십 및 협업

• 장의 개요
• 파트너십 모델
• 바이오의약품 첨가제 시장 : 파트너십 및 협업

제8장 최근 확장

제9장 용량 분석

• 장의 개요
• 주요 전제 및 조사 방법
• 바이오의약품 첨가제 제조 : 세계의 설비용량
• 결론

제10장 시장 예측 및 기회 분석

• 장의 개요
• 예측 조사 방법 및 주요 전제조건
• 세계의 바이오의약품 첨가제 시장(-2035년)
• 바이오의약품 첨가제 시장 : 생물 제제 유형별
• 바이오의약품 첨가제 시장 : 첨가제 유형별
• 바이오의약품 첨가제 시장 : 기업 규모별
• 바이오의약품 첨가제 시장 : 사업 규모별
• 바이오의약품 첨가제 시장 : 지역별

제11장 결론

제12장 주요 인사이트

제13장 부록 1 : 표 형식 데이터

제14장 부록 2 : 기업 및 단체 일람

AJY

영문 목차

영문목차

GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: OVERVIEW

As per Roots Analysis, the biopharmaceutical excipients market is estimated to grow from USD 2.73 billion in the current year to USD 4.58 billion by 2035, at a CAGR of 4.8% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biologics

• Antibodies
• Vaccines
• Cell Therapies
• Other Biologics

Type of Excipient

• Carbohydrates
• Polymers
• Solubilizers / Surfactants
• Polyols
• Proteins / Amino Acids
• Others

Company Size

• Small
• Mid-sized
• Large / Very Large

Scale of Operation

• Preclinical
• Clinical
• Commercial

Key Geographical Regions

• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa
• Rest of the World

GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: GROWTH AND TRENDS

The demand for biopharmaceutical excipients has grown considerably in the past few years as they play a critical role in development of biologics. These biopharmaceutical excipients enhance solubility and bioavailability of biologics, by controlling pH and tonicity of the active pharmaceutical ingredients (APIs). However, due to the highly complex and capital-intensive manufacturing processes of biopharmaceutical excipients, many contemporary biologic developers prefer to rely on CMOs for the supply of GMP grade excipients. Further, in order to cater to the growing demand for biopharmaceutical excipients across both clinical and commercial scales, CMOs with expertise in this field are expected to expand their capabilities and existing capacities in the coming years.

During our research, we identified various players that offer manufacturing services of biopharmaceutical excipients, including lipids, trehalose, lactose, mannitol, succinate, Tween 20 and benzyl alcohol. These companies are placing greater emphasis on developing co-processed multifunctional biopharmaceutical excipients to enhance the stability and efficacy of innovative biotherapeutics. In fact, over the past three decades biopharmaceutical manufacturers have developed some exceptional excipients which claim to increase the biopharmaceutical formulation shelf life by three times.

GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY INSIGHTS

The report delves into the current state of the global biopharmaceutical excipients market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, around 45 players claim to provide various types of biopharmaceutical excipients to biologic developers; these companies operate in compliance to global regulatory standards.
• In order to cater to the evolving needs of sponsors, companies offering biopharmaceutical excipients have established their presence in various geographical regions.

• The market landscape is fragmented, featuring the presence of both established players and new entrants involved in the manufacturing of excipients for different types of biologics.
• Close to 90% of companies claim to have the required capabilities and expertise to offer excipients for liquid drug formulations at all scales of operations.
• Although majority (~75%) of the manufacturers are based in developed regions, many players have recently emerged in some Asian countries, such as India and China.
• Nearly 60% of the manufacturers claim to provide biopharmaceutical excipients for vaccines and protein / peptide-based therapeutics.
• Companies are steadily expanding their existing capabilities in order to enhance their respective portfolios and drive compliance to evolving industry benchmarks.
• A rise in partnerships, focused on biopharmaceutical excipients, validates the growing interest of stakeholders in this domain; maximum number of such deals were signed in the last three years.
• Since 2020, the partnership activity has increased at a steady pace in this domain. It is worth mentioning that majority of the deals were established in the last two years.
• Over 40 agreements have been inked in the last 5 years in this domain; 32% of which were distribution agreements. Other popular types of partnership models adopted by players engaged in this domain include acquisitions (23%) and supply agreements (13%).
• Established players have forged multiple deals for biopharma excipients; most of these were focused on distribution of proprietary biopharmaceutical excipients.
• Examples of firms that have signed multiple deals within North America include (in alphabetical order) ABITEC, Aceto, Evonik, Merck and Roquette.
• To keep pace with the growing demand for biopharmaceutical excipients, manufacturers have undertaken many expansion initiatives in the recent past; ~80% of such instances involved facilities based in Europe.
• More than 45% of expansion initiatives were focused on capacity expansion of manufacturing facilities, followed by those undertaken for expanding existing facilities (43%). It is worth mentioning that most of the expansion initiatives (78%) were carried out in Europe and North America.
• The supply-side of this market is driven by mid-sized and large biopharmaceutical excipient manufacturers; interestingly, close to 40% of the currently available capacity is installed in production plants located in Europe.
• Approximately 95% of the total installed capacity is dedicated to commercial scale manufacturing. The remaining 5% of the installed capacity is focused on preclinical / clinical scale manufacturing of biopharmaceutical excipients. In addition, over 50% of the total current global, installed biopharmaceutical excipient manufacturing capacity is installed in Europe.
• With the growing focus on biologics based therapeutic interventions, the biopharmaceutical excipients market is likely to grow at a steady pace over the next decade.
• The opportunity is expected to be segregated across a variety of biologics, scales of operation and key geographical regions.
• North America and Europe are anticipated to capture over 70% of the market share by 2035. In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (6.4%) in the long term. Further, in 2035, biopharmaceutical excipient manufacturing market for antibodies is expected to capture the majority share (~52%) of the total market.

Example Players in the Biopharmaceutical Excipients Market

• ABITEC
• Avantor
• BASF
• Corden Pharma
• DFE Pharma
• Evonik
• Kirsch Pharma
• Merck KGaA
• Pfanstiehl
• Roquette
• Spectrum Chemical Manufacturing
• SPI Pharma

GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global biopharmaceutical excipients market, focusing on key market segments, including [A] type of biologics, [B] type of excipient, [C] company size, [D] scale of operation and [E] key geographical regions.
• Market Landscape: A comprehensive evaluation of the current biopharmaceutical excipients, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facilities, [E] type of excipient, [F] scale of operation, [G] type of formulation, [H] type of biologic and [I] global regulatory compliance.
• Company Competitiveness Analysis: A comprehensive competitive analysis of biopharmaceutical excipient manufacturers, examining factors, such as [A] supplier power and [B] company competitiveness.
• Company Profiles: In-depth profiles of companies engaged in this domain, focused on [A] company overview, [B] financial information (if available), [C] biopharmaceutical excipients portfolio, [D] manufacturing facilities and [E] recent developments and an informed future outlook.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the biopharmaceutical excipient market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of excipient, [D] type of drug molecule, [E] most active players (in terms of the number of partnerships signed) and [F] geography.
• Recent Expansions: In-depth analysis of recent expansions undertaken by various biopharmaceutical excipient manufacturers, focused on [A] year of expansion, [B] type of expansion, [C] company size, [D] location of headquarters, [E] location of expanded facility, [F] type of excipient, [G] type of drug molecule, [H] most active players and [I] geographical distribution.
• Capacity Analysis: A detailed analysis of the global installed capacity for biopharmaceutical excipients considering the capacities of various biopharmaceutical excipient manufacturers, based on several relevant parameters, such as [A] company size, [B] scale of operation and [C] key geographical regions.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Biopharmaceutical Excipients
• 3.3. Properties of Ideal Excipients
• 3.4. Classification of Biopharmaceutical Excipients
  • 3.4.1. Classification based on Route of Administration
  • 3.4.2. Classification of Excipients based on Structure
  • 3.4.3. Classification of Excipients based on Function
  • 3.4.4. Classification based on Ability to Interfere with Metabolization and Efflux Mechanisms
• 3.5. Applications of Biopharmaceutical Excipients
• 3.6. Regulatory Scenario
• 3.7. Concluding Remarks

4. MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters
  • 4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
  • 4.2.5. Analysis by Type of Excipient based on Chemical Composition
  • 4.2.6. Analysis by Type of Excipient based on Function
  • 4.2.7. Analysis by Type of Excipient based on Chemical Structure
  • 4.2.8. Analysis by Scale of Operation
  • 4.2.9. Analysis by Type of Formulation
  • 4.2.10. Analysis by Type of Biologic
  • 4.2.11. Analysis by Global Regulatory Compliance

5. COMPANY COMPETITIVENESS ANALYSIS

• 5.1. Chapter Overview
• 5.2. Assumptions and Key Parameters
• 5.3. Methodology
• 5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
  • 5.4.1. Company Competitiveness Analysis: Small Companies
  • 5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
  • 5.4.3. Company Competitiveness Analysis: Large Companies
  • 5.4.4. Company Competitiveness Analysis: Very Large Companies

6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS

• 6.1. Chapter Overview
• 6.2. ABITEC
  • 6.2.1. Company Overview
  • 6.2.2. Biopharmaceutical Excipient Offerings
  • 6.2.3. Manufacturing Facilities
  • 6.2.4. Recent Developments and Future Outlook
• 6.3. Avantor
  • 6.3.1. Company Overview
  • 6.3.2. Financial Information
  • 6.3.3. Biopharmaceutical Excipient Offerings
  • 6.3.4. Manufacturing Facilities
  • 6.3.5. Recent Developments and Future Outlook
• 6.4. BASF Pharma
  • 6.4.1. Company Overview
  • 6.4.2. Financial Information
  • 6.4.3. Biopharmaceutical Excipient Offerings
  • 6.4.4. Manufacturing Facilities
  • 6.4.5. Recent Developments and Future Outlook
• 6.5. Corden Pharma
  • 6.5.1. Company Overview
  • 6.5.2. Biopharmaceutical Excipient Service Offerings
  • 6.5.3. Manufacturing Facilities
  • 6.5.4. Recent Developments and Future Outlook
• 6.6. DFE Pharma
  • 6.6.1. Company Overview
  • 6.6.2. Biopharmaceutical Excipient Offerings
  • 6.6.3. Manufacturing Facilities
  • 6.6.4. Recent Developments and Future Outlook
• 6.7. Evonik
  • 6.7.1. Company Overview
  • 6.7.2. Financial Information
  • 6.7.3. Biopharmaceutical Excipient Offerings
  • 6.7.4. Manufacturing Facilities
  • 6.7.5. Recent Developments and Future Outlook
• 6.8. Kirsch Pharma
  • 6.8.1. Company Overview
  • 6.8.2. Biopharmaceutical Excipient Offerings
  • 6.8.3. Manufacturing Facilities
  • 6.8.4. Recent Developments and Future Outlook
• 6.9. Merck KGaA
  • 6.9.1. Company Overview
  • 6.9.2. Financial Information
  • 6.9.3. Biopharmaceutical Excipient Offerings
  • 6.9.4. Manufacturing Facilities
  • 6.9.5. Recent Developments and Future Outlook
• 6.10. Pfanstiehl
  • 6.10.1. Company Overview
  • 6.10.2. Biopharmaceutical Excipient Offerings
  • 6.10.3. Manufacturing Facilities
  • 6.10.4. Recent Developments and Future Outlook
• 6.11. Roquette
  • 6.11.1. Company Overview
  • 6.11.2. Biopharmaceutical Excipient Offerings
  • 6.11.3. Manufacturing Facilities
  • 6.11.4. Recent Developments and Future Outlook
• 6.12. Spectrum Chemical Manufacturing
  • 6.12.1. Company Overview
  • 6.12.2. Biopharmaceutical Excipient Offerings
  • 6.12.3. Manufacturing Facilities
  • 6.12.4. Recent Developments and Future Outlook
• 6.13. SPI Pharma
  • 6.13.1. Company Overview
  • 6.13.2. Biopharmaceutical Excipient Offerings
  • 6.13.3. Manufacturing Facilities
  • 6.13.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS

• 7.1. Chapter Overview
• 7.2. Partnership Models
• 7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
  • 7.3.1. Analysis by Year of Partnership
  • 7.3.2. Analysis by Type of Partnership
  • 7.3.3. Analysis by Year and Type of Partnership
  • 7.3.4. Analysis by Type of Excipient
  • 7.3.5. Analysis by Type of Drug Molecule
  • 7.3.6. Most Active Players: Analysis by Number of Partnerships
  • 7.3.7. Analysis by Geography
    • 7.3.7.1. Intercontinental and Intracontinental Deals
    • 7.3.7.2. International and Local Deals

8. RECENT EXPANSIONS

• 8.1. Chapter Overview
• 8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
  • 8.2.1. Analysis by Year of Expansion
  • 8.2.2. Analysis by Type of Expansion
  • 8.2.3. Analysis by Company Size and Location of Headquarters
  • 8.2.4. Analysis by Location of Expanded Facility
  • 8.2.5. Analysis by Type of Excipient
  • 8.2.6. Analysis by Type of Drug Molecule
  • 8.2.7. Most Active Players: Analysis by Number of Recent Expansions
  • 8.2.8. Geographical Analysis
    • 8.2.8.1. Region-wise Distribution
    • 8.2.8.2. Country-wise Distribution

9. CAPACITY ANALYSIS

• 9.1. Chapter Overview
• 9.2. Key Assumptions and Methodology
• 9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
  • 9.3.1. Analysis by Company Size
  • 9.3.2. Analysis by Scale of Operation
  • 9.3.3. Analysis by Location of Manufacturing Facility
• 9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

• 10.1. Chapter Overview
• 10.2. Forecast Methodology and Key Assumptions
• 10.3. Global Biopharmaceutical Excipient Manufacturing Market, Till 2035
• 10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic
• 10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient
• 10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size
• 10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation
• 10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region
  • 10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America, Till 2035
  • 10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe, Till 2035
  • 10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, Till 2035
  • 10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America, Till 2035
  • 10.8.5. Biopharmaceutical Excipient Manufacturing Market in MENA, Till 2035
  • 10.8.6. Biopharmaceutical Excipient Manufacturing Market in Rest of the World, Till 2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

• 12.1. Chapter Overview
• 12.2. Company A
  • 12.2.1. Company Snapshot
  • 12.2.2. Interview Transcript: Biopharma Sales Director

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료